Background Crossover stenting across the origin of the profunda femoral artery (PFA) and occasionally into the common femoral artery (CFA) is commonly used after suboptimal balloon angioplasty of ostial occlusive lesions of the superficial femoral artery (SFA) involving the bifurcation. Late stent occlusion at the bifurcation is not rare and results in severe lower extremity ischemia. Therefore, we tried to assess its possible causes, prevention and reintervention. Methods Using a prospectively maintained single-center database, 12-month femoral bifurcation patency was retrospectively compared and lesion and procedural predictors of stent occlusion were determined among 63 patients (64 lesions) who between July 2011 and February 2013 underwent crossover (36 non-jailed and 15 jailed SFA, and 12 distal and 1 complete CFA) stenting of de novo ostial SFA lesions. Results Twelve-month overall patency rate at the femoral bifurcation was 88%, with no significant difference between jailed-ostial SFA (80%) and distal CFA (67%) stenting (P=0.731), and significant differences between either and non-jailed ostial stenting (100%, P=0.035 and 0.002). When PFA ostium was jailed by the stent, patients with preexisting CFA or PFA lesions had a 12-month bifurcation patency rate of 20%, significantly lower than those with simple ostial SFA lesions (83%, P=0.015). Stent induced intimal hyperplasia caused bifurcation occlusion in 6 surgical reintervention cases. Conclusions In crossover stenting of ostial lesions in SFA, bifurcation patency loss was significantly higher in distal CFA and jailed ostial SFA stenting than non-jailed ostial SFA stenting. Preexisting CFA or PFA lesion is a significant risk factor for bifurcation patency loss when PFA ostium is jailed by crossover stenting.
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Chin Med J 2014;127 (18) : 3291-3295 E ndovascular therapy is widely accepted as first-line treatment of chronic arterial occlusive disease in lower extremities. For ostial lesions of the superficial femoral artery (SFA) which often involve the bifurcation, crossover stenting across the origin of profunda femoral artery (PFA) and sometimes into the common femoral artery (CFA) is required after suboptimal angioplasty. Despite relatively high patency rate for crossover stenting, 1-4 late restenosis or occlusion at the femoral bifurcation is not rare. This study aimed to compare 12-month patency among different crossover stent placements in ostial SFA lesions, and To assess possible causes of bifurcation occlusion using data gathered during index procedure and reinterventions.
METHODS

Patient population
From a prospective database maintained at our center, we retrospectively screened 158 consecutive patients who, between July 2011 and February 2013, underwent endovascular treatment of de novo ostial lesions in SFA. In this cohort, 78 patients with 82 lesions were treated by crossover stenting. At 12 months, 1 patient died and 14 patients were lost to follow-up, the rate of clinical compliance was 81%. Therefore, 63 patients (mean age, (73.1±8.2) years, range 61-85 years; 47 males) with 64 lesions were finally analyzed in this study. Patients' baseline characteristics and risk factors are shown in Table 1 .
Classification of lesion characteristics and stent placement
Bifurcation lesions of the CFA were categorized according to the Medina classification. Lesion characteristics were described as 1 or 0 for presence or absence, respectively, of significant stenosis, in order of CFA, SFA and PFA. 1 Crossover stent placement was classified according to Yamawaki et al 5 with modifications as: (1) complete CFA stenting, when stent covered the entire CFA; (2) distal CFA stenting, when stent proximal edge crossed the PFA origin and into the distal CFA; (3) jailed ostial SFA stenting, when stent proximal edge was at the shoulder of femoral bifurcation covering the PFA ostium; or (4) non-jailed ostial SFA stenting, when stent proximal edge was between the shoulder and the carina of femoral bifurcation not covering the PFA ostium ( Figure 1 ).
Patient follow-up
Postprocedural surveillance included symptom assessment, clinical examination, ABI measurement, and duplex ultrasound at 3, 6 and 12 months after primary and secondary intervention. CTA was only performed in patients with symptom recurrence, significant decrease in ABI measurement or positive duplex ultrasound findings indicating stent or graft failure. CFA diameter at the stent proximal edge was recorded by duplex scanning in patients with distal CFA or jailed ostial SFA stenting. Outcome of this study was patency of femoral bifurcation at 12 months follow-up. Loss of bifurcation patency was defined as complete lumen loss secondary to total stent occlusion in distal or complete CFA, proximal PFA and SFA.
Data collection and statistical analysis
Detailed demographic and clinical information was obtained from hospital medical records. Procedural information including lesion characteristics, stent size and stent placement classification, was collected for each patient from the catheter laboratory database at our center. Continuous variables are expressed as means ± standard deviation. Categorical data are presented as numbers and percentages, and comparisons among groups and lesions were made using the Fisher exact test. A P value of <0.05 was considered statistically significant. The analyses were performed using SPSS software version 17.0 (SPSS Inc., USA).
RESULTS
Among 64 de novo ostial SFA lesions studied, 36 (56%) were treated with non-jailed ostial SFA stenting, 15 (23%) with jailed ostial SFA stenting, 12 (19%) with distal CFA stenting and 1 (2%) with complete CFA stenting. Table  2 summarizes lesion characteristics in different stent placement groups. Overall prevalence of 0-1-0 lesions was 86%. Six mm bare metal nitinol stents with lengths ranging from 60 mm to 150 mm were deployed at bifurcation sites.
Loss of bifurcation patency
Bifurcation patency loss occurred at different times during follow-up in 8 patients. Twelvemonth overall patency rate at femoral bifurcation was 88%: 100% for non-jailed ostial SFA, 80% for jailed-ostial SFA, 67% for distal CFA and 0% for complete CFA stenting, respectively (Table 3 ). There was no significant difference in 12-month patency rates between jailed-ostial SFA and distal CFA stenting (P=0.731), but both were significantly different than that for the nonjailed ostial stenting group (P=0.035 and 0.002). There were 28 lesions in which the PFA ostia were jailed by crossover stents, bifurcation patency rate in the 1-1-0 and 0-1-1 lesion groups together was 20% (1/5), significantly lower than the 83% (19/23) rate in the 0-1-0 lesion group (P=0.015).
Findings during reintervention
All 8 patients with bifurcation patency loss had critical limb ischemia (CLI, mean ABI, 0.29±0.07, range: 0.11-0.42). Lesion and procedural characteristics are outlined in Table 4 . All patients, except patient 3 who refused further treatment, had secondary intervention either by endoluminal or surgical approach. Endoluminal intervention was attempted in patients 1, 2, 4 and 5, but optimal revascularization could not be achieved secondary to failed guidewire passage through the occluded lesion in patients 1 and 5 (Figure 2A and B) , failed guidewire engagement into the occluded PFA in patient 2 ( Figure 2C and D) , or acute occlusion in the SFA 24 hours after secondary stent implantation from the proximal PFA and into the distal CFA in patient 4 ( Figure 2E-H) . Patient 4 had a major amputation, and the others underwent surgical repair shortly thereafter.
Surgical repair was performed in 6 patients with femoropopliteal bypasses. A segment of 3 to 6 cm of femoral artery with part of the proximal stent was removed followed by reconstruction of the femoral bifurcation ( Figure 2 I and J) . Prominent intimal hyperplasia was seen at the level of PFA ostium in all cases, despite healthy lumen appearance on preprocedural CT angiography. On inspection of the 6 removed stents, there was no stent fracture, and occlusion was mainly attributed to intimal hyperplasia throughout the full length of the removed stents. Immediately post procedure, ABI increased from 0.34 to 0.73 (mean 0.51±0.12). Graft patency was maintained in 5 patients at mean follow up of 12.3 (range 4 to 24) months. Graft failure occurred in patient 5 at 9-month follow-up, however, no further intervention was attempted because the PFA remained patent.
DISCUSSION
Crossover stenting is commonly used as a bail-out in cases of flow-limiting dissections or significant residual stenosis after balloon angioplasty for ostial SFA lesions involving the femoral bifurcation. However, opinions remain divided over its efficacy and feasibility with regard to bifurcation patency and compromise of later interventional or surgical options via the CFA. [1] [2] [3] [4] [5] [6] [7] [8] C FA e n d a r t e r e c t o m y h a s l o n g b e e n considered as "gold standard" treatment for CFA occlusive lesions with well-reported durable success. 8 CFA stenting is still not widely accepted due to concern of stent fracture at this highly mobile area and limitation of future access to CFA. [11] [12] [13] For ostial SFA lesions extending into the CFA, i.e., Medina class 1-1-0 or 1-1-1 lesions, a hybrid approach involving CFA endarterectomy with concomitant SFA stenting has gained greater acceptance. 7, 9, 14 Because in the current study, 1-1-0 and 0-1-1 lesions had much greater potential over 0-1-0 lesions to develop bifurcation occlusion when 0-1-0 5.5 6 × 80 Jailed ostial SFA 7 0-1-0 6.3 6 × 150 Jailed ostial SFA 8 0-1-0 6.5 6 × 150 Jailed ostial SFA Figure 2 . Endoluminal or surgical reintervention for loss of bifurcation patency. Patient 1: loss of bifurcation patency after complete CFA stenting (A); failed guidewire passage into either the SFA or PFA by a bidirectional approach (B). Patient 2: loss of bifurcation patency after distal CFA stenting (C); the occluded PFA could not be engaged after a 6 mm balloon angioplasty across the bifurcation (D). Patient 4: loss of bifurcation patency after distal CFA stenting of a 0-1-1 bifurcation lesion (E); absence of PFA flow after kissing balloon angioplasty at femoral bifurcation (F); a 5 mm×60 mm self-expanding stent was deployed spanning from the proximal PFA into the distal CFA (G); acute occlusion in the SFA 24 hours after intervention (H). Patient 7: loss of bifurcation patency after jailed ostial SFA stenting (I); a below-the-knee femoral-popliteal bypass was performed after removing the proximal stent (J).
the PFA ostium was jailed by the stent, for preexisting significant CFA and PFA lesions, CFA endarterectomy with profundaplasty may be more favorable than crossover stenting in terms of restenosis, occlusion and target lesion reintervention. 15 Recently, an atherectomy device has become one of the preferred revascularization strategies for CFA lesion intervention minimizing need for stent implantation. 1, 16, 17 Medina class 0-1-0 predominates among femoral bifurcation lesions, and the prevailing viewpoint is that stent implantation into the CFA should be avoided if possible. 6, 7 However, in "flush" ostial SFA lesions, stent coverage of the PFA origin is mandatory to achieve an optimal result. In the latter setting, stent placement should be as short as possible in the CFA to allow for subsequent percutaneous intervention as well as surgical procedure, therefore giving rise to three stent placement patterns, namely distal CFA stenting, jailed ostial SFA stenting and non-jailed ostial SFA stenting. Yamawaki et al 5 compared these patterns and observed that distal CFA stenting had a significantly higher 1-year bifurcation patency (83.3%) than ostial SFA stenting (56.3%). In the current study, bifurcation patency loss ostial SFA stenting group occurred exclusively in cases of jailed stenting. Possible explanations based on the interventional and surgical findings include: (1) shifting of plaque into the PFA by a jailed ostial SFA stent; and (2) radial force on the shoulder of PFA origin exerted by proximal stent edgeinduced excessive intimal hyperplasia. In the current study, distal CFA stenting had similar likelihood of developing total occlusion at femoral bifurcation compared with jailed ostial SFA stenting. Stent undersizing, incomplete coverage of CFA lesion and preexisting PFA lesion on preprocedural CTA or angiography may be risk factors for late stent occlusion. Stent undersizing has been recently recognized to promote thrombosis; stagnant flow and low wall shear stress resulting from stent malapposition to the endothelium highly favor accumulation of red blood cells, platelets, and lipids, all of which are thrombogenic. 18, 19 Therefore, in the case of large CFA, instead of using a 6-mm stent as is common in SFA stenting and as exemplifies by patient 3, crossover stent should be chosen according to distal CFA diameter.
On review of primary procedural angiograms, final stent implantation did not reflect operators' intention in patients 2, 7 and 8. Inadequate oblique C-arm projection not fully visualizing the bifurcation in patient 2, and migration during deployment of a 150 mm long stent in patients 7 and 8 resulted in an unintentional jailed stenting. It is our experience that deployment of 60 or 80 mm short stents under proper C-arm projection minimizes stent misplacement.
Regardless of initial Rutherford classification, patients will present with symptoms of CLI after stent patency loss at femoral bifurcation. In the current series, reintervention by endoluminal approach appeared ineffective because of inability to engage the PFA or maintain durable patency at the bifurcation. In our experience, surgical repair involving proximal stent removal and femoropopliteal bypass is more favorable to reconstruct inflow and outflow. Perfusion into the PFA should, by all means, be restored; it is a clinically important collateral to the lower extremity in case of late graft failure.
Major limitations of this study incudes its small sample size and single center scope. Only center patients were screened to favor a higher rate of clinical compliance. Furthermore, being aware of the published data on CFA treatment, operators might have been biased in treatment modality selection which probably led to a small proportion of 1-1-0 or 0-1-1 lesions in this study. Finally, follow-up was limited to 12 months, precluding a precise assessment of long-term consequences of non-jailed ostial SFA stenting. Despite these limitations, this study is likely to reflect reallife practice in ostial SFA stenting.
In conclusion, in crossover stenting of ostial lesions in SFA, distal CFA and jailed ostial SFA stenting have significantly higher rate of bifurcation patency loss than non-jailed ostial SFA stenting. Preexisting CFA or PFA lesion is a significant risk factor of bifurcation patency loss when PFA ostium is jailed by a crossover stent. Surgical repair has more favorable and durable outcome than endoluminal approach in the reintervention of stent occlusion at femoral bifurcation.
